TAK-242 has been demonstrated to suppress LPSinduced inflammation (68, 69) . Recently, TAK-242 has been shown to almost completely suppress production of nitric oxide or TNFα induced by LPS in mouse RAW264.7, human U937 and P31/FUJ cells (70) . In a HEK293 cell model where TLR4, MD-2 and CD14 were co-expressed, this antagonist showed specificity to TLR4 as other TLRs, TLR1/2, TLR2/6, TLR3, TLR5, TLR7 and TLT9 were not affected by this drug (70) .